Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This study aims to prove the efficacy and safety of low dose nivolumab (40mg as the lowest
available presentation) in combination with AVD (adriamycin,vinblastine sulfate and
dacarbazine) as frontline treatment for classic Hodgkin's lymphoma.